EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 ASX ANNOUNCEMENT 15 April 2025 ─────────────────────────────────────── CMS Proposes Approval of NTAP Reimbursement Key Highlights: The Centers for Medicare & Medicaid Services (CMS) is proposing to approve the WiSE® CRT System for the New Technology Add-On Payment (NTAP) for FY 2026 CMS has recommended WiSE receive the maximum add-on payment of 65% of the device cost, which is in addition to the normal MS-DRG payment. In combination, these are intended to fully cover the cost of the WiSE System. ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Award of NTAP is subject to the final rule and will be effective from 1 October 2025 and will remain in effect for three years once approved ─────────────────────────────────────────────────────────────────────────────────── This represents a significant milestone in EBR’s commercialisation strategy, moving one step closer to ensuring US reimbursement for Medicare inpatients An application for Transitional Pass-through (TPT) reimbursement to provide reimbursement f…
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
EBR Systems, Inc.
EBRCZOTCEQUITYCurrent
Other Events
Item 8.01 Other Events. On April 14, 2025, EBR Systems, Inc. (the “Company”) issued a press release announcing that the Centers for Medicare & Medicaid Services (CMS) has proposed approval of the New Technology Add-On Payment (NTAP) for EBR’s WiSE CRT System. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.…
Company context
Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.